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The discovery of an ever-expanding plethora of coding and non-coding RNAs with nodal and 
causal roles in the regulation of lung physiology and disease is reinvigorating interest in the 
clinical utility of the oligonucleotide therapeutic class. This is strongly supported through 
recent advances in nucleic acids chemistry, synthetic oligonucleotide delivery and viral gene 
therapy that have succeeded in bringing to market at least three nucleic acid-based drugs. 
As a consequence, multiple new candidates such as RNA interference modulators, 
antisense, and splice switching compounds are now progressing through clinical evaluation. 
Here, manipulation of RNA for the treatment of lung disease is explored, with emphasis on 
robust pharmacological evidence aligned to the five pillars of drug development: exposure 
to the appropriate tissue, binding to the desired molecular target, evidence of the expected 
mode of action, activity in the relevant patient population and commercially viable value 
proposition.  
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microRNA; nucleotide, nt; PNA, peptide nucleic acid; PMO, phosphorodiamidate 
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1. Introduction 
 
Pharmacologic intervention commonly involves the administration of synthetic small 
molecules, recombinant proteins or antibody-based therapeutics that target or mimic the 
action of proteins. However, these approaches can only be employed to target certain 
classes of proteins (i.e. extracellular protein in the case of antibodies). This has lead to 
emerging interest in targeting proteins at the mRNA level using oligonucleotide-based 
therapeutics such as antisense and short (or small) interference RNA (siRNA). Since the 
actions of oligonucleotide therapeutics are mediated through Watson-Crick binding, this 
approach has the advantage of being able to target all known mRNAs, as well regulatory 
non-coding RNAs (ncRNA) such as microRNAs (miRNA) (de Hoon, Shin, & Carninci, 2015; 
Djebali et al., 2012; Kawai et al., 2001). However, in developing these oligonucleotide-based 
therapeutics, a number of major problems have emerged including poor stability in 
biological fluids, potential to induce immune response and off-target actions. However, the 
principal problem is delivery of these large (often > 6 kDa), negatively charged (resulting 
from the sugar-phosphate backbone) molecules both into the target tissue and then across 
the plasma membrane (also negatively charged) and into the cell, where they mediate their 
biological action. Significantly, the delivery problems have meant that much of the effort in 
this area has focused upon liver disease based on the observation that this organ readily 
absorbs oligonucleotides following intravenous (IV) administration (Nicklin et al., 1998). 
Thus, Ionis (previously known as ISIS) Pharmaceuticals has recently obtained regulatory 
approval in the USA for mipomersan, an antisense oligoncleotide (ASO) that targets 
apolipoprotein B for the treatment of familial hypercholesterolemia (Santos, Raal, Donovan, 
& Cromwell, 2015). Nevertheless, the large surface area of the airways and their 
accessibility to topical delivery suggests that the respiratory system might also represent a 
potential target tissue for oligonucleotide-based therapeutics.  
 
1.1. Anatomy and physiology of the respiratory system  
 
Lung architecture (Hasleton, 1972; Lambert, Wilson, Hyatt, & Rodarte, 1982; Lambert, 1989; 
R. J. Lorenz, 1966) is commonly visualized as a bunch-of-grapes (Mauroy et al., 2015) formed 
by 23 serial bifurcations from the trachea to the last alveolar duct (generation 22; Fig. 1A) 
(R. J. Lorenz, 1966). Surface area and volume in adults ranges from 24 - 69 m2 and 2.16 - 
5.23 l, respectively, varying significantly on account of age, height and disease (Hasleton, 
1972; Labiris & Dolovich, 2003; Usmani, 2014). Of the ~3 l standard internal lung volume 
(Hasleton, 1972), 85-90% is occupied by alveoli (lung parenchyma or interstitium) (Ochs, 
2014).   
 
One of the key physiological barriers to the delivery of oligonucleotides is the thin layer of 
pulmonary surfactant and mucus that line lower and upper airways, respectively. The 
cationic and lipoproteinaceous matrix that constitutes the pulmonary surfactant of the 
lower airways and alveoli has a number of biological functions including mechanostructural 
stabilization (Parra & Pérez-Gil, 2015), surface tension reduction to enable gas exchange 
(Whitsett, Wert, & Weaver, 2015) and as a contributor to immune protection (Han & 
Mallampalli, 2015). Many of the surfactant lipid components have been successfully 
synthesized and are used in liposomal and lipid nanoparticle drug formulation. Surfactant 
proteins (SP) are principally derived from the SPA, SPB, SPC and SPD genes, expressed by 
type II alveolar epithelial cells. These, along with alveolar macrophages, also recycle 
surfactant and together participate in innate immune responses to extrinsic inflammatory 
stimuli of viral (Derscheid & Ackermann, 2013; Hillaire, Haagsman, Osterhaus, 
Rimmelzwaan, & van Eijk, 2013), bacterial (Chroneos, Sever-Chroneos, & Shepherd, 2010; 
Sender & Stamme, 2014; Whitsett, 2010), fungal (Faro-Trindade et al., 2012; Ledford, 
Addison, Foster, & Que, 2014; Singh et al., 2015; van de Wetering et al., 2004), parasitic 
(Blanco, Lugones, Díaz, & Monzote) and particulate nature (Arick, Choi, Kim, & Won, 2015; 
Ma et al., 2015; Vattanasit et al., 2014). Alveolar macrophages also clear extraneous matter, 
which may or may not elicit innate and adaptive immune responses (Forbes et al., 2014). 
  
Surfactant genes are also expressed in the larger airways (Whitsett et al., 2015) and even 
the nose (Gaunsbaek, Kjeldsen, Svane-Knudsen, Henriksen, & Hansen, 2014). However, the 
upper airways are mainly lined with mucous - a highly complex, anionic, glycoproteinaceous 
and gelatinous extracellular matrix (S. K. Lai, Wang, Wirtz, & Hanes, 2009) synthesized by 
goblet cells and submucosal glands that express MUC5AC and MUC5B and are located 
throughout the bronchi. The predominant structural component of mucous is large mucin 
polymer fibers of <10 nm size, that interact to produce a complex physicochemical 
organization (Shogren, Gerken, & Jentoft, 1989). Its role is the capture and elimination of 
large particles reaching the upper airways through inhalation. The underlying epithelium 
contributes to immune surveillance through both immune dampening and pathogen 
associated molecular pattern recognition systems (Davies, 2014). Removal of particulates is 
mediated by mucocilliary clearance and episodic bronchial smooth muscle contraction, i.e. 
cough. Materials are propelled into the trachea and then to the gastrointestinal tract for 
digestion. This mechanobiological phenomenon relies on the microrheology of mucous, 
which is more elastic in the nasopharynx and distal airways but less so in the intervening 
bronchi, and is altered by disease (e.g. increased viscoelasticity due to reduced hydration) 
(Rubin, 2014). These changes can alter significantly mucociliary clearance rates, bacterial 
cell interactions with the host, particle motion within the mucous matrix and, consequently, 
drug delivery mechanics (S. K. Lai et al., 2009).  
 
Respiratory disease is associated with multiple changes in the airways and lungs that can 
impact upon the delivery and action of oligonucleotide therapeutics. In fibrotic disease 
thickening of the alveoli reduces the gas diffusion barrier, in many cases preceded or 
accompanied by surfactant dysfunction.  In chronic obstructive pulmonary disease (COPD), 
alveolar sac volume increases on account of loss of the type II epithelia, in turn reducing the 
surface area available for gas exchange (Ochs, 2014). Asthmatic patients experience 
dyspnea as principally airborne allergens (Hurwitz, 1955; Johansson et al., 2008; Romanet-
Manent, Charpin, Magnan, Lanteaume, & Vervloet, 2002) trigger constriction of the upper 
airways (Noble et al., 2014) alongside inflammatory/allergic responses (Erle & Sheppard, 
2014), mucous overproduction/increased viscoelasticity (S. K. Lai et al., 2009) and 
conducting airway/bronchial wall thickening (Olin & Wechsler, 2014). Together, these 
phenomena reduce the bronchial diameter during an asthmatic attack that can eventually 
lead to death (Dowell, Lavoie, Solway, & Krishnan, 2014). In cystic fibrosis (CF), genetic 
mutations (Bombieri et al., 2011) produce solute imbalances in the airways that contribute 
to mucous hypersecretion, altered mucous motility and dysregulated immune homeostasis, 
leading to opportunistic infection.  
 
All these indications are associated with exaggerated or disrupted innate and adaptive 
immune responses. Indeed, recent attention has shifted onto the role of respiratory 
epithelia given their importance in inflammation and the exacerbations associated with 
many chronic lung disease following exposure to inhaled pathogens (Zuo, Lucas, Fortuna, 
Chuang, & Best, 2015). Interestingly, studies have also indicated that the lung is not sterile, 
as commonly believed, but populated by numerous microbes (Riiser, 2015). Although 
sampling approaches and analytical methodologies confound this research (Salter et al., 
2014), reports of pulmonary microbiome imbalances have emerged. Whether these are 
causal or consequential remains to be determined, however, their relevance to immune 
plasticity during treatment is of therapeutic interest, especially where novel therapeutics 
may interact with, or affect immune status.  
 
The physiological, mechanistic and molecular differences between pathologies, coupled to 
the functional differences between species and organizational complexity of the tissue are 
such that in vitro 2D/3D/co-culture system and animal model use is limited, or at least 
challenging in their translational value (Nichols et al., 2014; Ochs, 2014; J. C. Parker & 
Townsley, 2008; Reus et al., 2014; Williams & Roman, 2015). This is especially the case when 
such approaches are used in isolation (Saturni, Contoli, Spanevello, & Papi, 2015), or 
without consideration of systems-level elements (Dittmar, McIver, Michalak, Garner, & 
Valdez, 2014; Seok et al., 2013; Takao & Miyakawa, 2015; Tsitsiou et al., 2012). 
 
1.2 Pharmacological targeting of selective regions within the respiratory system 
 
Airway dimensions adhere to fractal branching models (Horsfield, 1990), information 
essential in engineering aerosolized and dry powder systems that target drugs to the 
specific location within the airways and lung by inhalation (Denyer & Dyche, 2010; Laube, 
2014). Thus, by controlling nebulized solution or dry powder particle size, appropriate 
deposition targeting can be achieved across the pulmonary tract, with minimal drug loss to 
the oral/nasal cavity or the environment  (Fig. 1B). Drug formulations are presently 
evaluated for their deposition mechanics through optical particle sizing, time-of-flight 
spectrometry, cascade impaction and liquid impinger technologies (Denyer & Dyche, 2010; 
Mitchell, Bauer, Lyapustina, Tougas, & Glaab, 2011; Pu, Kline, Khawaja, Van Liew, & Berry, 
2015; Zhu, Haghi, Goud, Young, & Traini, 2015). 
 
2. Modulating RNA homeostasis with oligonucleotide-based therapeutics 
 
A number of classes of oligonucleotide-based therapeutics have been developed although 
these can be principally divided into i) antisense and ii) RNA interference (RNAi)-based 
approaches. The first are single-stranded antisense oligonucleotides (ASO) 20-30 
nucleotides (nt) in length that can either catalyse target cleavage (via RNAse H) or 
stoichiometrically sequester RNA targets (Fig. 2A, B). Currently, this approach has proved 
the most effective, with two approved ASOs that are RNase H-active (fomivirsen: approved 
in 1998; mipomersen: approved in 2012). Antisense-based approaches have also been 
developed for RNA splicing manipulation, the closest to market being drisapersen, a 
compound in late stage developed for the treatment of Duchenne muscular dystrophy  (Fig. 
2C; drisapersen, Biomarin Pharmaceutical (Disterer et al., 2014; Q.-L. Lu, Cirak, & Partridge, 
2014; van Deutekom et al., 2007)). Single stranded oligonucleotides in the form of aptamers 
can also be used as replacements to antibodies. A marketed example is pegaptanib which 
targets extracellular VEGF and is licensed for use in wet macular degeneration (approved in 
2004) (Sundaram, Kurniawan, Byrne, & Wower, 2013). Following the identification of siRNA-
mediated RNAi as a mechanism capable of regulating gene expression at the level of 
transcription and/or translation, there has also been considerable effort to develop these 
double stranded RNAs (dsRNA) as potential therapeutic modalities (Fig. 2D) (Moschos, 2013; 
Sabin, Delás, & Hannon, 2013).  
 
The biggest challenges in the clinical progression of both antisense and RNAi-active drugs 
are their poor targeting to disease-relevant tissue sites and their inefficient transportation 
across the plasma membrane into the cytosol, where the pharmacological targets of these 
drugs reside. In addition, it has been necessary to address a number of other issues 
including stability, off-target action and immune activation. 
 
2.1 Development of antisense oligonucleotide therapeutics 
 
To simultaneously address the problems of antisense stability and delivery, much of the 
effort has focused upon the development of modified synthetic oligonucleotides (Bennett, 
Chiang, Chan, Shoemaker, & Mirabelli, 1992). Specifically, emphasis has been placed on 
development of chemistries impervious to nuclease degradation, with concomitantly 
enhanced pharmacokinetic properties, better cellular uptake, improved target affinity, and 
tailored immunogenicity profiles.  
 
2.1.1 First Generation Antisense 
Early studies on RNase H-active ASO evidenced transfection reagents as necessary to elicit 
appreciable function in vitro (Bennett et al., 1992), otherwise micromolar concentrations 
achieved internalization over a 50 h period through a saturable, cytoplasmic membrane 
protein pathway (Loke et al., 1989). The main site of ASO activity was shown to be the 
nucleus (P L Iversen, Zhu, Meyer, & Zon, 1992). In vivo activity, however, was negligible due 
to the poor stability against nucleases.  
The first attempts to resolve this problem involved the use of phosphorothioate backbone 
modifications, which imparted increased stability in biofluids and improved 
pharmacokinetics in vivo (Fig. 3A, Fig. 4). However, toxicity was observed due to interactions 
with heparin-binding growth factors and other compounds (Benimetskaya et al., 1997; 
Fennewald & Rando, 1995; Guvakova, Yakubov, Vlodavsky, Tonkinson, & Stein, 1995). It was 
not until many years later that serum albumin was identified as the principle (T. A. 
Watanabe, Geary, & Levin, 2006), but not the only carrier of phosphorothioate ASO in 
circulation and into the liver (Bijsterbosch et al., 2000). Uptake is presently understood to 
involve at least two (Koller et al., 2011), if not more endocytic mechanisms (Juliano, Ming, & 
Nakagawa, 2012) although this mechanism of action (MAO) is thought to account for only 
20% of uptake (Geary et al., 2009). Of note, these antisense were also found to be TLR9 
agonists (Krieg et al., 1995; Rutz et al., 2004) (Table 1) and demonstrated a propensity for 
complement activation (Advani et al., 2005; Henry et al., 1997) 
 
2.1.2 Second Generation Antisense 
 
The second generation of antisense involved a cadre of chemical modifications of the 2’ 
ribose position (Fig. 3B, 4B; mixomers), or the development of entirely novel backbone 
structures resistant to nuclease activity, such as phosphorodiamidate morpholinos (PMO) 
and peptide nucleic acids (PNA; Fig. 3A). In many cases, although these modifications greatly 
increased the binding affinity of the ASO for its target RNA, this often coincided with the loss 
of RNaseH inducing activity, as RNase H cleaves 8-12 bases from the 3’ end of the ASO 
(Cerritelli & Crouch, 2009; Crooke, 1999; Vickers & Crooke, 2015; H. Wu, Lima, & Crooke, 
1999). 
Lack of RNase H induction, however, can be advantageous where the mechanism of action 
does not require target cleavage, such as exon modulation (splice switching or splice 
correction) therapy. Interestingly, some mutations in CF patients are indeed amenable to 
splice-switching therapy as evidenced in vitro. Thus, correct exon splicing has been reported 
in at least two separate studies modeling distinct genetic backgrounds involving aberrant 
splicing of CFTR (Friedman et al., 1999; Igreja, Clarke, Botelho, Marques, & Amaral, 2015). 
The therapeutic value of this approach is strongly supported by complementary studies 
which involve the overexpression of splicing factors as opposed to use of splice correction 
oligonucleotides (Nissim-Rafinia et al., 2004). There is therefore scope for expanding the 
evidence on the mechanistic utility of splice switching therapies in CF animal models, 
provided commercially appealing delivery solutions are pursued.   
 
To address the mixomer issue around loss of RNase H activity in 2nd generation ASO 
attempts were made to produce so-called gapmer oligonucleotides (Fig. 4B). These were 
organized to feature unmodified 8-12 nt DNA sequences at the centre, flanked by modified 
nucleosides at the 3’ and 5’ ends. (Cerritelli & Crouch, 2009; Crooke, 1999; Vickers & 
Crooke, 2015; H. Wu et al., 1999). A number of these 2nd generation ASO have been 
advanced clinically with mixed outcomes (section 3).  
 
PMOs are claimed to have higher affinity and a reduced propensity for off-target RNA 
binding (J. E. Summerton, 2007), with flagship programs in phase 2 and 3 clinical studies for 
the treatment of Duchenne’s muscular dystrophy through splicing modulation (eteplirsen 
(AVI-4658) and SRP-4053; Sarepta Therapeutics). Whilst preclinical data corroborated 
increased affinity (Q. L. Lu et al., 2005; Tanganyika-de Winter et al., 2012; B. Wu et al., 
2010), including in the lung (Q. L. Lu et al., 2005; B. Wu et al., 2010), the claims of increased 
specificity have been challenged by others exploring off-target binding in depth (Eisen & 
Smith, 2008; Schulte-Merker & Stainier, 2014). Furthermore, although PMO alone showed 
delivery in vitro and in vivo, this can be substantially improved through conjugation with 
synthetic cell penetrating peptides (CPP) (Moulton et al., 2007) (peptide-conjugated 
phosphorodiamidate morpholinos (PPMO), or 2nd generation PMO’s).  
 
PPMOs have been recently suggested to form <90 nm, negatively charged micelles under 
physiologically relevant conditions (Ezzat et al., 2015), leading to cellular uptake through 
scavenger receptors (Ezzat et al., 2012, 2015). However, the micromolar critical micelle 
concentration reported by Ezzat et al. is higher than therapeutically relevant concentrations 
of drug. Although there have been eight clinical trials involving PPMOs, none have involved 
lung disease. However, preclinical evidence suggests efficacy after topical administration to 
the lung. Thus, targeting of the respiratory syncytial virus (RSV) by intranasal (IN) dosing in 
mice demonstrated localized antisense delivery to the bronchial airways and indicated some 
prophylactic value (S.-H. Lai et al., 2008; Lupfer et al., 2008) if the drug was dosed within a 
limited window ahead of virus challenge. Therapeutic value, however, was questionable 
since only a modest, <65% reduction of viral titers was reported (S.-H. Lai et al., 2008). 
Curiously, the extent of virologic response was comparable to the ~50% reduction of 
transcript levels for endogenous RNAs when these were targeted by PPMOs  (Rajsbaum et 
al., 2014). Yet efficacious antivirals typically induce acute, multi-log (i.e. >99.9%) drops in 
viral target titers. Similar results were reported in piglets (Opriessnig et al., 2011), with 
RNase H-inactive antisense to RSV inducing a delay, but not elimination of viral infection. Of 
relevance, development of viral mutational escape (Lupfer et al., 2008) has led to adoption 
of multi-PPMO strategies and complex dosing regimes (Patrick L Iversen et al., 2012). 
PPMOs might also be active against bacteria, as a single, acute (5 min), post-infection, IN 0.1 
mg dose of PPMO in mice was shown to be protective against respiratory challenge with 
multidrug resistant Acinetobacter by targeting bacterial transcripts (Geller et al., 2013). 
However, at least some of these activities are class-level bacteriostatic effects from the 
covalently attached CPPs that were employed as the delivery vehicle (Wesolowski, Alonso, 
& Altman, 2013). In addition, PMOs also demonstrate both antibacterial and antimalarial 
activities (Augagneur, Wesolowski, Tae, Altman, & Ben Mamoun, 2012), a finding that 
further complicates the separation of gene specific from off-target effects (Eisen & Smith, 
2008). PPMOs have been also proposed as inhibitors (Francis et al., 2014) of endogenous 
mediators of RNAi, miRNAs, and miRNA target site protectors (Staton & Giraldez, 2011). 
More recently, additional backbone modification of the PPMO chemistry has been sought in 
the so-called PMOplus structure (Fig. 3A). This has been evaluated clinically at phase I 
against lethal filovirus infectious disease (Marburg and Ebola virus), with published data in 
non-human primates being encouraging with regards to protective capacity (Heald et al., 
2014; Patrick L Iversen et al., 2012; Warren et al., 2010, 2015). However, published data lack 
confirmation of the MOA of PMOplus chemistries. Their utility in topical administration to 
the lung remains unknown.  
 
As with PMOs, PNAs also demonstrated enhanced delivery (Veldhoen, Laufer, & Restle, 
2008) when conjugated to simple (Robaczewska et al., 2005; Sazani et al., 2002) and 
complex (Cordier et al., 2014) CPP peptides. This includes CPPs used for PMOs (Maekawa et 
al., 2015) and extends to natural protein transduction domains (Fabani & Gait, 2008; Oh, Ju, 
& Park, 2009) and small molecule compounds such as triphenylphosphonium (Mehiri et al., 
2008) or flavin (Marlin et al., 2012). Yet others have also proposed backbone modification 
with fluorine (Ellipilli & Ganesh, 2015) or guanidine (Dragulescu-Andrasi et al., 2006) as 
alternatives to peptide conjugation. With respect to the lung, activity for PNAs has been 
evidenced only after intraperitoneal injection with CPP-PNAs; however, daily dosing is 
required with PNA ASOs, whereas phosphorothioate ASOs are compatible with weekly 
dosing (Sazani et al., 2002).  
 
Although PNA ASO efficacy has been evaluated in various rodent models of systemic disease 
(Brolin et al., 2015; Fabani & Gait, 2008; Gao et al., 2015; Rembach et al., 2004; 
Robaczewska et al., 2005), there are no reports examining PNA ASO utility after topical 
administration to the lung in the absence of any delivery modifications. This would suggest 
PNA ASO might not be well suited for topical dosing to the airways. Tellingly, whereas Ahn 
et al. proposed topical PNA ASO dosing against respiratory viruses (Ahn et al., 2011), at least 
one group has reported that a highly complex microparticle formulation is necessary to 
achieve any degree of efficacy. Thus, the proposed solution is a quaternary system 
consisting of two polymer blends, CPPs, and the bioactive PNA (Fields et al., 2015). Such 
approaches bear considerable development and chemistry manufacturing control costs that 
challenge commercial viability even within orphan disease indications. Unfortunately, 
evaluation of this solution in a rodent CF model (McNeer et al., 2015), exhibited modest 
effects. Thus, activity was reported in <0.4% of alveolar epithelia and <1% of macrophages 
despite particle deposition in both the small and large airways and association with 50-90% 
of lung cells (Fields et al., 2015). There remain, therefore, considerable challenges to 
progressing in the clinic PNA chemistries for lung disease.  
 
 
2.1.3 Third generation Antisense 
 
More recently, 3rd generation antisense have been developed that make use of 2’-5’ 
bridging groups (Fig. 3B) resulting in greatly increased stability in biological fluids, as well as 
higher affinity for their molecular targets. This increased affinity has resulted in the 
development of shorter antisense, with enhancer delivery (as a result of their smaller size) 
and more advantageous pharmacokinetic and pharmacodynamic properties (Dirin & 
Winkler, 2013; Geary, Norris, Yu, & Bennett, 2015). These antisense are also short enough 
to target miRNAs (anti-miRs) (Elmén, Lindow, Schütz, et al., 2008) and directly inhibit the 
function of the miRNA and siRNA induced silencing complex (RISC) by preventing 
engagement of RISC with it’s RNA targets. The first 2’-5’ modification to be described were 
‘locked’ nucleic acid (LNA) (Wengel, 1999) although other structures (e.g. 2’-4’ bridges) with 
similar performance metrics have been developed (Burel et al., 2013; Seth et al., 2009). To 
date, LNA remains the single 2’-5’ bridging modification commercially available for research 
use. Interestingly, short LNA antisense enter cells in vitro without delivery systems i.e. in 
simple ‘naked’ saline formulations (Stein et al., 2010). The process has been termed 
‘gymnosis’ from the Greek word for ‘naked’ (gymnos). This is an alternative and more 
efficient mechanism to ‘free uptake’ previously described for 2nd generation antisense (Loke 
et al., 1989). Crucially, activity is principally elicited in the cytosol rather than the nucleus, 
and possibly via nucleases other than RNase H (Castanotto et al., 2015). It remains to be 
elucidated if this is a feature of all 3rd generation ASO, LNA-modified ASO alone, or an 
observation relevant to in vitro studies only. Nonetheless, 2,2,7-trimethylguanosine caps 
could enable nuclear targeting if necessary (Moreno et al., 2009). Presently, 
phosphorothioate LNA ASO have been shown to associate mainly with the liver and kidney 
(Straarup et al., 2010) and have been suggested to bind onto their intended 
pharmacological target to exert the expected MOA in up to phase IIb clinical studies (van 
der Ree et al., 2014). This has encouraged acquisition of the technology by Roche. However, 
both precursors and mature miRNA might be targeted by this approach (Gebert et al., 
2013), and the methods used to evidence target engagement in vivo (Elmén, Lindow, 
Silahtaroglu, et al., 2008) could be simply artifacts of cell association carrying through tissue 
homogenization and high affinity nucleic acid purification, rather than true target 
association.  
 
2.2. Development of RNAi-based therapeutics  
Historically, RNAi therapeutics were developed on the back of discovery that delivery of 
exogenous dsRNA sequences of 20-27 nt length or greater, that were fully complementary 
to practically any part of target mRNAs, resulted in target cleavage and subsequent 
degradation (Fire et al., 1998). In mammals, >30 nt dsRNA were not thought to be useful in 
an RNAi manner as such molecules instigate antiviral responses (Bevilacqua & Cech, 1996), 
through Protein Kinase R engagement (Sledz, Holko, de Veer, Silverman, & Williams, 2003). 
However, present-day understanding of RNAi involves a considerably larger number of 
functions and encompasses the endogenous (miRNA) and exogenous (siRNA) mediators of 
RNAi operating at the transcriptional and post-transcriptional/pre-translational level (Fig. 
2D) (Moschos, 2013; Sabin et al., 2013). Interestingly, endogenously expressed long (>30 nt 
dsRNA-derived) siRNAs are encountered in reproductive biology, in transposon control and 
in cancer, operating through DNA methylation (L. Chen, Dahlstrom, Lee, & Rangasamy, 
2012; Song et al., 2011; Tam et al., 2008; T. Watanabe et al., 2008; Werner et al., 2014)- a 
largely overlooked area. The reader is thus encouraged to consider siRNA and miRNA 
function in the context of RISC bioactivity as opposed to the mechanism of RISC formation 
as, overall, RISC functions are interchangeable for siRNA and miRNA. 
 
The minimal bioactive complex of RNAi, the RISC complex (Fig. 2D, 5), contains one of four 
Argonaute proteins found in the mammalian genome, loaded with a short, ~21 nt long RNA 
strand of either endogenous (miRNA; Fig. 5A) or exogenous (siRNA) origin. RISC is often 
found in combination with multiple other regulatory proteins and uses Watson-Crick base 
pairing between the RISC-loaded RNA strand (referred to as the guide or antisense strand) 
and cellular RNAs to identify RNA targets. Target recognition relies on partial 
complementarity, often only between bases 2-9 from the 5’ end of the guide strand (seed 
sequence) (Lewis, Shih, Jones-Rhoades, Bartel, & Burge, 2003). Where a transcript contains 
a sequence complementary to a miRNA seed sequence, the binding site is often referred to 
as the miRNA response (or recognition) element (MRE) (Leuschner, Ameres, Kueng, & 
Martinez, 2006; Matranga, Tomari, Shin, Bartel, & Zamore, 2005). These are most 
commonly found within coding transcript 3’ untranslated regions (3’-UTR). However, cases 
of target recognition that do not involve the seed sequence at all but involve base pairing at 
the central (Shin et al., 2010) or 3’ end of the guide strand have been documented (Sung 
Wook Chi, Hannon, & Darnell, 2012). The rules of target recognition are not fully described, 
restricting the utility of computational target prediction. Furthermore, miRNA and siRNA are 
subject to 5’ and 3’ end modification (Azuma-Mukai et al., 2008; Burroughs et al.), which 
further complicates target prediction and validation.  
 
Detailed descriptions of miRNA genomic organization and biogenesis can be found 
elsewhere (Moschos, 2013) and are summarized in Figure 3. In conjunction with viral and 
non-viral gene therapy approaches, miRNA and siRNA expression can be extensively 
engineered. Structurally, there are minimal differences in mature miRNA and synthetic 
siRNA structure (Fig. 2D), and siRNA-like synthetic miRNAs (miRNA mimics) are common 
tools in miRNA complementation / pharmacology studies (Perry et al., 2008). Diverse 
chemical modifications have been described to direct RISC precursor strand loading 
(Moschos, 2013) but there is no evidence to suggest AGO protein selection and RISC 
complex subcellular localization can be manipulated (J. H. Park & Shin, 2015). 
 
As with single stranded ASO, the major issues with the development of RNAi mediators 
(siRNA and miRNA) as therapeutics has been delivery, stability, off-target actions and 
induction of immunological responses.  
 
2.2.1 Demonstrating On-Target Action of siRNAs 
 
Of the four human Ago proteins that form RISC, only AGO2 possess an RNA endonuclease, 
or ‘slicer’ function, which allows for active target cleavage (F. Li et al., 2007). Slicing of 
targets occurs on their phosphate backbone opposite positions 10-11 from the 5’ end of the 
guide strand (Leuschner et al., 2006; Matranga et al., 2005), and has been shown to occur 
both with miRNA and siRNA guide strands (Maniataki & Mourelatos, 2005). Crucially, direct 
observation of this cleavage constitutes biochemical evidence of an on-target, AGO2 RISC-
mediated pathway and is typically determined using 5’ rapid amplification of 
complementary DNA ends (5’-RACE; qualitative) followed by Sanger sequencing (Soutschek 
et al., 2004) or next generation sequencing (RACE-Seq; semi-quantitative (Denise et al., 
2013)). Global RNA-Seq (Tabernero et al., 2013) can report the relative extent of target 
cleavage (knockdown), assess effects on other transcripts and any impact on splice variants. 
It is important to note, however, that experimental (Raabe, Tang, Brosius, & 
Rozhdestvensky, 2014; Sorefan et al., 2012; van Dijk, Jaszczyszyn, & Thermes, 2014) and 
analytical (Erhard & Zimmer, 2015; X. Liu, Zhang, & Chen, 2015; Yang & Jeong, 2013) bias in 
deep sequencing may severely skew observations (Lahens et al., 2014).  
 
2.2.2 Off-target actions of siRNAs, or documenting miRNA bioactivity. 
 
It is generally accepted that the majority of off-target actions of siRNAs are mediated 
through their ‘miRNA-like actions’ i.e. RISC docking onto the 3’-UTRs of other mRNAs, 
leading to the unintentional inhibition of their translation (Filipowicz, Bhattacharyya, & 
Sonenberg, 2008; Jidong Liu, Valencia-Sanchez, Hannon, & Parker, 2005; R. Parker & Sheth, 
2007). However, translational inhibition (as opposed to catalytic target cleavage) occurs also 
when siRNA forms RISC with AGOs 1, 3 and 4 which all lack the slicer function. Non-slicer 
RISC docking in coding regions (S W Chi, Zang, Mele, & Darnell, 2009; Nelson et al., 2007) 
may also lead to translational repression (Fang & Rajewsky, 2011; Schnall-Levin et al., 2011; 
Tay, Zhang, Thomson, Lim, & Rigoutsos, 2008) whilst docking on the 5’ UTR may lead to up-
regulation of translation (Ørom, Nielsen, & Lund, 2008) (Fig. 2D). These mechanisms can be 
assessed by determining siRNA guide strand interactions with mRNAs through cross-linking 
and immunoprecipitation followed by next generation sequencing (CLIP-Seq) (S W Chi et al., 
2009). Notably, this only reports target presence and/or enrichment across the entire gamut 
of RNAs pulled down through the assay and requires multiple processing (protease, 
nuclease) steps. To date, a method offering direct MOA evidence remains to be developed. 
Importantly, reporter constructs (Humphreys et al., 2012) disregard target transcript 
secondary and tertiary structures and can be misleading, as demonstrated through 
extensive virological research (Schopman, ter Brake, & Berkhout, 2010). Thus, single point 
mutations outside MRE / RISC binding sites are adequate to enable virus escape against 
RNAi mediators. 
 
It is now also well established (Sabin et al., 2013) that mature RISC may translocate back 
into the nucleus (Bai, Liu, & Laiho, 2014; Castanotto, Lingeman, Riggs, & Rossi, 2009; Földes-
Papp et al., 2009; Marcon, Babak, Chua, Hughes, & Moens, 2008; Ohrt et al., 2008; Politz, 
Zhang, & Pederson, 2006; Weinmann et al., 2009). Functional studies have shown that this 
can produce transcriptional activation (RNA activation) (L.-C. Li et al., 2006; Matsui, Chu, et 
al., 2013; Place, Li, Pookot, Noonan, & Dahiya, 2008; Schwartz et al., 2008; Y. Zhang et al., 
2014) and repression (Ahlenstiel et al., 2012; Kim, Saetrom, Snøve, & Rossi, 2008; Younger & 
Corey, 2011), epigenetic remodeling (Ahlenstiel et al., 2012; Kim et al., 2008; L.-C. Li et al., 
2006; Morris, Santoso, Turner, Pastori, & Hawkins, 2008; Younger & Corey, 2011; Zardo et 
al., 2012), miRNA precursor maturation control (Tang et al., 2012), as well as splice 
switching (Alló et al., 2009; Ameyar-Zazoua et al., 2012; Jing Liu, Hu, & Corey, 2012). Most of 
these functions involve AGO1 (Kim et al., 2008), but may also include AGO2 (Ohrt et al., 
2008; Schraivogel et al., 2015) in a slicer-positive (Gagnon, Li, Chu, Janowski, & Corey, 2014) 
or negative (Matsui, Chu, et al., 2013) fashion. Functional partners of nuclear RISC include 
transcriptional proteins (Matsui, Chu, et al., 2013; Y. Zhang et al., 2014), promoter-
associated and natural antisense transcripts (Matsui, Chu, et al., 2013; Morris et al., 2008; 
Schwartz et al., 2008) or intergenic ncRNA (Matsui, Prakash, & Corey, 2013). Interestingly, 
some functions appear to integrate the spliceosome, RNA polymerase elongation and 
chromatin remodeling (Ameyar-Zazoua et al., 2012), and even participate in dsDNA break 
repair (Wei et al., 2012).  
 
Beyond these functions, viruses have also been shown to encode RNAi mediators and 
manipulate RNAi homeostasis. Thus, RISC can be used to  prevent 5’-3’ exonuclease 
cleavage (Sedano & Sarnow, 2014; Thibault et al., 2015) of RNA viral genomes, promote 
virus replication (Fan et al., 2015), regulate viral polyprotein translation (Masaki et al., 2015) 
and organize the viral genome structure (Masaki et al., 2015; Mortimer & Doudna, 2013; 
Narbus et al., 2011). Whether some of these functions are also relevant to endogenous 
transcripts remains to be determined. Importantly, as with HIV in vitro (Schopman et al., 
2010), clinical studies have evidenced mutations external to the RISC binding sites may alter 
RISC binding capability (Israelow et al., 2014). Yet more recently, components of AGO2 RISC 
have been isolated from mitochondria (Xiaorong Zhang et al., 2014), although this may not 
be ubiquitous across cell types (Ro et al., 2013). Mechanistic studies suggest functions in line 
with other cytosolic RNAi MOA (Jagannathan et al., 2015), although AGO2 RISC 
translocation within myocyte mitochondria and translational upregulation activity has been 
proposed (Xiaorong Zhang et al., 2014). Roles in mitochondrial transcription regulation have 
been so far documented only in plants (Dietrich, Wallet, Iqbal, Gualberto, & Lotfi, 2015), 
with similar studies lacking in mammals. 
 
 2.2.3 siRNA and miRNA mediated immune responses 
 
RNAi mediators are now understood to be natural agonists of multiple pathogen associated 
molecular pattern receptors (Table 1) such as the toll-like receptor (TLR) family members 3 
(Cho et al., 2009; Kleinman et al., 2008), 7 and 8 (Hornung et al., 2005; Judge et al., 2005). 
Their activation drives the release of various proinflammatory cytokines, with diverse 
kinetics which can vary substantially based on host species, system complexity (in vitro vs. in 
vivo) and delivery system type (Broering et al., 2014; Forsbach et al., 2008, 2012; Moschos 
et al., 2007). Crucially, the effects of at least TLR3 activation are not local: stimulation by an 
siRNA in the peritoneum can result in remarkable remodeling in tissues as anatomically 
distant as the eye (Kleinman et al., 2008). This finding contributed substantially to the 
abandonment of the first-in-class siRNA clinical candidate, bevasiranib. The cytokines 
presently implicated in TLR-mediated off target effects include alpha interferon, tumor 
necrosis factor alpha, interleukin (IL) 6, IL-10, beta interferon, interferon-induced protein 
with tetratricopeptide Repeats 1 and interferon sensitive gene 15, on account of large and 
small (dinucleotide) sequence motifs (Forsbach et al., 2008; Judge et al., 2005; Robbins et 
al., 2007; Schlee, Hornung, & Hartmann, 2006) also found in many miRNAs. Indeed, in stark 
contrast to common misconceptions, it is now confirmed that miRNA are TLR7/8 agonists 
(at least) that induce inflammatory (Fabbri et al., 2012), pro-apoptotic (W. A. He et al., 2014) 
and pain responses (C.-K. Park et al., 2014) through exosomal communication pathways 
(Patton et al., 2015); these functions depend on the miRNA sequence and the recipient cell 
type, and should come as no surprise to the reader versed in the immunostimulatory 
potential of synthetic siRNA-like molecules.  
 Advantageously, nucleoside analogues (Table 1 and Fig. 3B) involving 2’ ribose modifications 
(e.g. 2’-O-methyl, 2’-fluoro and 2’-5’ oxygen-bridged ‘locked’ nucleic acids (LNA)) 
incorporated in RNAi mediators act as a TLR7/8 antagonists (Robbins et al., 2007; Sarvestani 
et al., 2015; Sioud, Furset, & Cekaite, 2007), with at least one of these, 2’-O-methyl, altering 
RISC off-target effect profiles (Fedorov et al., 2006; Jackson et al., 2006). The impact of 
other modifications on RISC off-target effects has not been publicly disclosed. Although 
nucleoside suppressors of both TLR3 and TLR7/8 have been described (Karikó, Buckstein, Ni, 
& Weissman, 2005) (Table 1), their impact on siRNA-mediated TLR3 activation has not been 
assessed. Presently, reports on the impact of 2-thiouridine on slicer function are 
contradictory (Prakash, Naik, Sioufi, Bhat, & Swayze, 2009; Sipa et al., 2007). Overall, 
judicious use of one or two 2’ modified nucleosides as formulation adjuncts (e.g. 2’-O-
methyl nucleosides, a natural nucleoside) or as siRNA sequence modifications can largely 
eliminate TLR7/8 activation potential and ablate the pyrimidine-purine specificity of RNase 
A (i.e. UpA, CpG, etc.) (Turner, Jones, Moschos, Lindsay, & Gait, 2007). Thus, simple changes 
with minimal impact of strand Tm can evade TLR7/8 induction and also drive better 
compound stability and increase confidence of an on-target (i.e. non-inflammatory) MOA.  
Presently, TLR3 evasion can be engineered only through iterative screening and testing.   
 
Beyond the TLR family, the intracellular pathogen associated molecular pattern sensors 2’-
5’-oligoadenylate synthase 1 (OAS1) (Kodym, Kodym, & Story, 2009), double-stranded RNA-
activated inhibitor of translation (DAI) (Manche, Green, Schmedt, & Mathews, 1992), 
melanoma differentiation-associated gene 5 (MDA5) (Kato et al., 2008), and retinoic acid-
inducible gene 1 (RIG-I) (Hornung et al., 2006; Marques et al., 2006; Pichlmair et al., 2006) 
are also activated by RNAi mediators or their precursors. Fortunately, most are long dsRNA-
specific. Among those sensitive to smaller dsRNA OAS1 is specific for the nucleotide motif 
NNWW(N9)WGN (Kodym et al., 2009) whereas RIG-I is inhibited by 3’ dinucleotide 
overhangs typical to miRNAs and endogenous siRNAs (Marques et al., 2006) (Fig. 2) or 
evaded through lack of 5’ triphosphate use on either RISC precursor strand (Kato et al., 
2008).  
 
3. Clinical progress of oligonucleotide therapeutics for lung disease. 
 
The original studies on lung-targeted oligonucleotide therapeutics (Moschos, Spinks, 
Williams, & Lindsay, 2008) expected delivery into lung cells following topical administration, 
despite historical data suggesting quick absorption into the circulation (Nicklin et al., 1998). 
This was principally due to the large size (~12 kDa) of the then fashionable siRNA compared 
to single stranded antisense. Thus, 90-99% reduction of gene expression (i.e. 1-2 logs) was 
commonly observed in cell culture whilst preclinical studies showed 2-fold (40-60%) 
reduction of target RNA levels (summarized in (Moschos et al., 2008)). Encouragingly, two 
co-administered antiviral siRNAs against separate viruses produced a 90-99% reduction in 
target mRNA and in tandem, alpha interferon production – a possibly advantageous feature 
for an antiviral RNAi drug (Bitko, Musiyenko, Shulyayeva, & Barik, 2005). Others reported 
that uptake across the tissue was not uniform for both ASO and siRNA encapsulated in a 
lipid delivery system (Griesenbach et al., 2006), and CPP conjugation to siRNA also yielded 
mediocre effects (Moschos et al., 2007). The inconsistencies were interpreted as 
experimental setup differences and variability between constitutively expressed vs. induced 
RNA targets. Based upon these initial observations, a number of oligonucleotide-based 
therapeutics have been developed/tested in clinical studies. 
 
3.1 RNAi mediators: ALN-RSV01 and the treatment of RSV infection. 
 
Presently, the most clinically advanced RNAi mediator remains Alnylam’s ALN-RSV01, a first 
generation, unmodified siRNA targeted against a conserved region of the nucleoprotein 
gene encoded in the RNA genome of respiratory syncytial virus (RSV) (DeVincenzo et al., 
2008). Dosing the airways was expected to match the respiratory epithelium tropism of the 
virus (Johnson, Gonzales, Olson, Wright, & Graham, 2007), in a well-defined patient 
population not catered for by any on-label treatment alternatives (DeVincenzo et al., 2008), 
and thus likely to achieve commercial success. 
 
3.1.1 Preclinical pharmacology. 
Although mildly immunostimulating (single time point data), 2’-O-methylation of ALN-RSV01 
did not affect siRNA IC50, suggesting TLR activation in mouse, if any, did not contribute to 
antiviral responses (Alvarez et al., 2009). On-target RNAi activity in vivo by 5’-RACE (Alvarez 
et al., 2009) further justified no need for use of any nucleoside modifications. Given 
established in vivo pharmacology practice and in line with contemporary studies, drug 
activity was measured at the tissue level. This involved homogenization of one or more 
lobes of the lung and reporting virological, RNA or protein assay levels at the whole tissue 
level. However, direct evidence of tissue loading and retention was not attempted as no 
systemic absorption was expected (DeVincenzo et al., 2008). It was indeed widely assumed 
that the large molecular weight of siRNAs (~12.5 kDa) was recalcitrant to systemic exposure. 
Rather, their anionic charge should complex with cationic alveolar surfactant (De Backer, 
Cerrada, Pérez-Gil, De Smedt, & Raemdonck, 2015) to piggy-back through surfactant 
recycling into alveolar epithelia and macrophage cytosols.  
 
3.1.2. Clinical performance and disease biology. 
 
Curiously, the highest dose (150 mg) tested at phase I resulted in rapid (<10 min) detection 
of ALN-RSV01 in blood plasma and in the first post-administration urination, at the lower 
detection limit of the analytical method. This was again interpreted as limited systemic 
exposure (DeVincenzo et al., 2008) without recourse to more sensitive methods. In an 
experimental clinical infection model the antiviral effect in the nasal cavity was shown as 
independent of TLR responses by multivariate regression analysis (DeVincenzo et al., 
2010a), but no effort was made to confirm a difference between human and preclinical 
inflammatory responses. Thus, ALN-RSV01 was suggested to prevent the migration of the 
infection from the nasopharyngeal epithelium into the lower airways (Hall, 2001), an 
interesting proposition given RSV was classically considered a disease of the lower airways 
(Wright et al., 2005). 
 
The progressive onset of symptoms from the upper to the lower airways had been 
documented in animal models (Gitiban et al., 2005; Richardson et al., 1978) and clinically 
(Hall, Douglas, & Geiman, 1975, 1976), suggesting the virus might indeed establish in the 
nares and progressively infect the lower airways over several days. However, no data 
existed confirming this hypothesis (El Saleeby, Bush, Harrison, Aitken, & Devincenzo, 2011) 
and the role of adaptive immunity was overlooked. Instead, comparable viral loads were 
demonstrated in the upper and lower airways in the mid- to late- stages of infection 
(Perkins et al., 2005). Crucially, the proposed treatment strategy was not experimentally 
tested to determine whether antiviral protection across the upper and/or lower airways 
would be uniquely adequate or jointly necessary. More recent findings indicate RSV might 
reach the lower airways considerably sooner than clinical symptom onset might otherwise 
suggest (Rameix-Welti et al., 2014).  
 
The first patient trial sought to test ALN-RSV01 utility in preventing development of RSV-
mediated bronchiolitis obliterans syndrome, associated inflammation, infection and 
ultimately tissue rejection in lung transplant patients (Zamora et al., 2011a). In contrast to 
the previous studies (DeVincenzo et al., 2008, 2010b) the drug was administered as an 
inhaled, saline-formulated aerosol targeted to the lung only (Gottlieb et al., 2015a). The 0.6 
mg/kg dose, ~1/3 of the 150 mg intranasal dose (DeVincenzo et al., 2008), again achieved 
rapid (<10 min) systemic access at the analytical assay’s lower limit of detection. 
Furthermore, at least one patient not on corticosteroids exhibited elevated cytokine 
responses (Zamora et al., 2011a). No statistically significant antiviral effect was achieved, 
but syndrome incidence and associated sequelae reduction was reported. Thus, syndrome 
incidence was chosen as a sign of efficacy in follow up studies. 
 
In phase IIb, however, the incidence rate of bronchiolitis obliterans syndrome was not 
reduced in RSV-infected individuals in a statistically significant manner, unless strict 
adherence to the therapeutic protocol was observed (10% incidence with treatment vs 28% 
incidence with placebo, p = 0.025) (Gottlieb et al., 2015b). Notwithstanding the impact on 
study power engendered through subject removal from analysis on account of protocol 
adherence, complete lack of any antiviral effects in oropharyngeal washes and nasal swabs 
were ascribed to pulmonary targeting of the aerosol formulation. Yet no viral genome load 
modulation was achieved in the deep lung either: it is unclear if the analytical method used 
was sensitive to RISC-mediated target cleavage (G. Chen, Kronenberger, Teugels, & De 
Grève, 2011; Herbert, Coppieters, Lasham, Cao, & Reid, 2011; Holmes, Williams, Chapman, 
& Cross, 2010; Shepard, Jacobson, & Clark, 2005). It is also unclear if the reported reduction 
in syndrome incidence was purely on account of ALN-RSV01 treatment: of the patients in 
the treatment arm of the study, 71% were also receiving pulse steroid treatment vs 58% in 
the placebo arm. 
 
 
3.2. 2nd Generation ASO therapeutics: Clinical Status.  
 
Parallel to ALN-RSV01, topically administered 2nd generation ASO were being clinically 
investigated for asthma and COPD (Séguin & Ferrari, 2009). These groups also presumed 
lung retention, measured target modulation at the tissue level and valued disease outcome 
metrics more than molecular pharmacology. At the time, three clinical candidates were 
being progressed through to clinical programs: i) AIR645 (previously known as ISIS 369645; 
2’-O-methoxyethyl chemistry; sponsored by Altair Therapeutics, an Ionis Pharmaceuticals 
spin-off) targeting the alpha chain common to IL receptors 4 (IL-4R) and 13 (IL-13R) (Fey et 
al., 2014), ii) ASM8 (TOP004 and TOP005 dual antisense formulation; 2'-deoxy-2'-fluoro-
beta-D-arabinonucleic acid (FANA) chemistry (Fig. 3); sponsored Topigen Pharmaceuticals, 
later acquired by Pharmaxis) targeting the common beta chain (c) of the ILR receptors 3, 5 
and granulocyte monocyte – colony stimulating factor (GM-CSF) and the C-C chemokine 
receptor 3 (CCR3), respectively (G M Gauvreau et al., 2011) and iii) ATL1102 (ISIS 107248, 
another 2’-O-methoxyethyl; Antisense Therapeutics) targeting the cluster designation 49d 
subunit of the very late antigen 4 adhesion molecule. 
 
3.2.1. Altair AIR645 and the targeting of IL-R4/IL-R13 in asthma. 
The Altair compound was progressed on strong mechanistic rationale around the IL4/IL-13 
receptor signaling system in asthma in the context of lung infiltrating, immunoglobulin E-
producing, CD4+ T lymphocytes (Chatila, 2004; Karras et al., 2007). Moreover, the group had 
already explored 2nd generation antisense dosing to the mouse lung with other targets 
(Duan et al., 2005). These early studies indicated dose-dependent antisense retention in the 
lung but at very low levels (1.1 g per g tissue 24 hours after a 3 mg/kg estimated dose 
(Duan et al., 2005)). Aerosol chamber dosing was understandably less efficient than nose-
specific aerosol administration (62.4 g per g tissue from a 3.1 mg/kg dose (Templin et al., 
2000)), which also differed from historical intranasal instillation studies (Nicklin et al., 1998). 
Immunohistochemistry had demonstrated macrophage loading and diffuse association of 
antisense with lung epithelia cell types (Templin et al., 2000); however, subcellular 
distribution was not assessed. Nonetheless, Duan et al. achieved restriction of multiple 
asthmatic disease biomarkers efficiently modeled in mice (eosinophilia, mucus production, 
cytokine production, airway hyper-responsiveness), including ~60% reduction in target 
mRNA levels in both luminal and draining peribronchial lymph node lymphocytes. However, 
the mRNA data were not normalized for endogenous housekeeping gene levels (Gorzelniak, 
Janke, Engeli, & Sharma, 2001), undermining the claim of an on-target mechanism of action.  
Using a murine-specific version of AIR645, ISIS 231894, Karras et al. attempted to address 
this by measuring the reduction of IL4R alpha chain protein levels (Karras et al., 2007). This 
involved fluorescent cell sorting of primary lung cell subtypes in mice receiving an estimated 
0.01-0.5 mg/kg nose-specific aerosol dose. At best, an ~50% reduction in IL4R alpha chain 
levels was observed in macrophages and lung epithelia at the highest dose, but it is unclear 
if multiple comparisons correction was applied in determining statistical significance, or if 
data distribution profiling was applied to inform linear or logarithmic scale statistical testing. 
Drug retention within each cell type was also not assessed. Thus, Karras et al. reported 
asthmatic response ablation but the mechanism remained unclear. Interestingly, 
immunomodulation appeared to be part of the effect of ISIS 231894 as revealed through 
cytokine profiling in a separate, antiviral study (Ripple et al., 2010). The relevance of these 
results appears to have been overlooked in the asthma model outputs. 
 
Both AIR645 (primate-specific) and ISIS 231894 were tested in rodents for toxicity and 
tolerability, but only AIR645 was tested in monkeys (Fey et al., 2014) at 0.4 - 50 mg/kg. This 
involved classical pulmonary-targeted drug toxicity endpoints and complement activation 
but excluded cytokines (Advani et al., 2005; Henry et al., 1997). Both antisense and target 
levels were analyzed at tissue level (Duan et al., 2005; Karras et al., 2007). Target mRNA 
levels were determined in the tissue (both species) and bronchoalveolar lavage cells 
(monkeys only), but were expressed with reference to total RNA levels determined by 
substantially alternative methodologies, an approach known to result in transcript 
quantification artifacts. No complement activation was observed but up to 24%, dose-
dependent, lung weight increases were documented in mice. Macrophage recruitment and 
enlargement (hystiocytosis; foamy macrophage phenotype) in the parenchyma and 
tracheobronchial lymph nodes was observed in both species, persisting for 13 weeks. Dose-
dependent pro-inflammatory infiltrates were reported only in mice, with hystiocytosis 
ascribed to ‘normal’ alveolar macrophage function as defined by Nikula et al. (Nikula et al., 
2014). Importantly, the Nikula et al. article is an expert-level regulatory position paper on 
the impact of the foamy macrophage induction in response to topically dosed lung 
therapies. It is worth noting, that Nikula et al. make a clear distinction between soluble 
drugs (i.e. aqueous antisense formulations) and insoluble particles, such as complex 
formulations and small molecule aggregates (dry powders). Thus, insoluble particles do not 
rapidly clear from the lung and are removed specifically by macrophages (alveoli) and 
mucocilliary clearance (bronchial airways). This contrasts soluble antisense and siRNA which 
rapidly access circulation, for which there is limited clinical data available. The physiological 
impact of oligonucleotide-induced hystiocytosis requires further elucidation before safety is 
established as suggested in Karras et al.   
 
Fey et al. calculated the clearance half-life from the lung at nine days and reported dose-
dependent loading in the liver and kidney. The data were in line with parallel studies 
supporting lower bioavailability for topically dosed 2nd generation ASO, but contrasted 
earlier reports (Nicklin et al., 1998): these differences could be ascribed to the use of 1st 
generation ASOs by Nicklin et al. Yet no appreciable change in IL-4R alpha chain mRNA levels 
was observed. Of note, as stated in Fey et al., the 1000x lower doses of AIR645 used by 
Karras et al. were apparently pharmacologically active, where Fey et al. reported no target 
modulation. The notable discrepancy was ascribed to the low-level target gene expression 
under naïve conditions in the Fey et al. study. In other words, targets expressed at low-
levels would appear to be recalcitrant to oligonucleotide-mediated downregulation. Instead, 
Fey et al. postulate that antisense should be used against transcripts undergoing 
upregulation (e.g. activated pro-inflammatory response genes). Furthermore, antisense 
efficacy should be measured only when these transcripts are being upregulated, not under 
baseline conditions. This contrasts evidence that transcripts expressed at low levels can be 
knocked down by antisense, provided the tissue is effectively transfected (e.g. 
apolipoprotein B downregulation in the kidney (Moschos et al., 2011)). It remains to be 
determined if low-level expression transcripts are malleable targets universally, or in a case-
by-case basis. Clinical efficacy data have yet to reach the peer-reviewed public domain for 
AIR645. 
 
3.2.2. Pharmaxis ASM8 and the targeting of CCR3 and the common c of IL-3R, IL-5R, and 
GM-CSF in asthma. 
 
The pursuit of a dual formulation consisting of two antisense drugs based on the FANA 
chemistry (TOP004 and TOP005; ASM8; Fig. 3) targeting two different transcripts was 
backed by substantial confidence in rationale (Corren, 2012). Thus, haematopoietic myeloid 
progenitor cells (HMC) are elevated in the circulation the lung tissue and sputum of 
asthmatics (and in murine models of asthma) under both naïve conditions and after allergen 
stimulation (Cameron et al., 2000; Dorman et al., 2004; D. S. Robinson et al., 1999; R Sehmi 
et al., 1996; Sergejeva, Johansson, Malmhäll, & Lötvall, 2004; Southam et al., 2005). HPCs 
express the receptors CCR3 and IL-5R, and differentiate into eosinophils in response to their 
activation (Roma Sehmi et al., 2003)(Dorman et al., 2004)(R Sehmi et al., 1997). Eosinophils 
are a cell type hallmark of allergic responses (Wenzel, 2006), whose concentration in the 
lung correlates with asthmatic disease severity (Bousquet et al., 1990). In asthmatic disease, 
HPCs overexpress these receptors (R Sehmi et al., 1997), parallel to the increased levels of 
these cytokines (Hamid et al., 1991; Humbert et al., 1997; D. Robinson et al., 1993). Ex vivo, 
soluble receptors were shown to attenuate HPC differentiation (Cameron et al., 2000). 
Furthermore, clinical and primate studies with injectable monoclonal antibodies against 
these receptors or their corresponding cytokines, as pioneered by Leckie et al. (Leckie et al., 
2000), indicated asthma exacerbation management could be achieved by manipulating this 
immune axis.  Indeed, reslizumab (anti-IL-5; Teva Pharmaceutical Industries Ltd.) is presently 
the third monoclonal antibody on track for market approval in the USA for the treatment of 
asthma, and the second anti-IL-5 agent after mepolizuman (GlaxoSmithKline Plc.); 
benralizumab (anti-IL5-R; MedImmune LLC.) has also been successful in reducing asthma 
exacerbations at phase IIb (Castro et al., 2014). Thus, both underlying biology and clinical 
data contemporary to the development of ASM8 suggested that dual action against CCR3 
and IL-5R could potentially achieve broader ablation of asthma exacerbation.  
 
Encouragingly, single antisense studies in vitro, in rodents and non-human primates (Z 
Allakhverdi et al., 2006; Zoulfia Allakhverdi, Allam, & Renzi, 2002; Allam & Renzi, 2001; 
Fortin et al., 2006) were positive, suggesting effective target knockdown at both the RNA 
and protein level (CCR3 and c) in tissue and ex vivo cell studies, in line with reduced airway 
eosinophilia and hyper-responsiveness after allergen challenge, However, the gel-based 
RNA quantification methodology used was poorly quantitative and no explicit MOA results 
such as 5’-RACE were reported throughout this work. Interestingly, additive effects were 
observed for the two drugs in rat models, such as reduction of lymphocyte and macrophage 
recruitment after challenge (Z Allakhverdi et al., 2006). Yet the results obtained in non-
human primates was contradictory (Guimond et al., 2008). Thus, as with AIR645, sporadic, 
but dose-dependent evidence of macrophage accumulation and inflammation was 
reported, principally at high doses; plasma detection of the drugs was only achieved at the 
2.5 mg/kg dose, with follow-on compounds detected also in the liver and kidney at the high 
dose only. Curiously, very modest target knockdown was reported (16% for CCR3 and 20% 
for c), only in the tracheal tissue and not in the lung parenchyma.  
 
Clinical studies (Gail M Gauvreau et al., 2008) evidenced ASM8 recovery in lung sputum and 
ablation of the six-fold increase of c mRNA (p = 0.039) induced by allergen challenge. 
However, the effect on CCR3 mRNA was not statistically significant, nor was that on the 
protein levels of either target. Similar observations were reported in some, but not all 
clinical markers of efficacy. Thus, a 46% reduction of sputum eosinophilia did achieve 
statistical significance, but the trend towards total leukocyte recruitment ablation did not; 
slightly elevated levels of macrophages were also observed. Dose-dependent, ~40% ablation 
of the inflammatory response was reproduced in the ensuing dose escalation study (G M 
Gauvreau et al., 2011), but this also coincided with a dose-dependent increase in sputum 
macrophages (G M Gauvreau et al., 2011). In later work (Imaoka et al., 2011), ASM8 
succeeded in reducing the early (0-2 hours) and late (3-7 hours) asthmatic responses 
measured as a loss of forced expiratory volume in one second after allergen challenge. 
However, both phases of the response were ablated only by the high, 8 mg once daily, 
inhaled dose; the early response was not affected by a 4 mg dose. In these patients  
eosinophil progenitor recruitment was also significantly reduced in sputum after allergen 
challenge, accompanied by statistically significant reduction of CCR3+ and IL-5R+ HPC 
numbers, but not total HPC level.  
 
Overall, despite the robust rationale, encouraging pre-clinical data and clinical success with 
other, injectable therapeutic modalities (antibodies) targeting the same immune signalling 
axis, the clinical progress of ASM8 was marred by lack of explicit MOA data, inconclusive 
bioanalytical results on target RNA and protein levels and mixed clinical outcomes. It is 
important to note at this point that both ASM8 and it’s competitor AIR645 have consistently 
induced macrophage recruitment into the airways, a phenotype not yet cleared as safe with 
regards to soluble therapeutic compounds. 
 
 
3.3. Third generation ASO. 
 
The utility of <20 nt LNA ASO was first evaluated in the same study that examined siRNA 
delivery to the lung at the cell type-specific level (Moschos et al., 2011). Unfortunately, as 
with the siRNA arm of this work, no activity was observed with LNA ASO in the lung. 
However, whilst siRNA and phosphodiester LNA ASO were rapidly (<15 min) eliminated in 
urine, phosphorothioate LNA ASO formed punctate structures within lung epithelia across 
upper and lower airways. These interactions appeared to be extracellular and membrane 
specific rather than endocytic, cytosolic or nuclear. Quantifiable amounts of 
phosphorothioate LNA ASO were reported only in lung macrophages, the liver and the 
kidney. Crucially, whereas there was no activity in lung macrophages, efficacy was observed 
in both the kidney and the liver: the latter was found to be indeed comparable to 
intravenous administration. 
 
These data suggested inhalation might actually be a viable needle-free dosing solution for 
3rd generation ASO therapies targeting systemic tissues rather than the lung, when the oral 
bioavailability of 2nd generation ASO varies between 2-12% even with the use of uptake 
enhancers (Nicklin et al., 1998; Raoof et al., 2004). Given the differences in ASO structure, 
molecular weight (length), target affinity and mismatch propensity between 2nd and 3rd 
generation ASO, extrapolation of the LNA findings (Moschos et al., 2011) to 2nd generation 
ASO was actively discouraged. However, comparable doses of the phosphorothioate AIR645 
(Fey et al., 2014) and LNA ASO (Moschos et al., 2011) resulted in 10x lower kidney retention 
of AIR645. Moreover, the low kidney expression of the RNA targeted by the LNA ASO did not 
prevent ASO activity as suggested for AIR645 (Fey et al., 2014). It is unclear if such 
limitations are target-specific or ASO-class specific, nor whether prolonged lung dosing of 
LNA ASO also drive macrophage recruitment.  
 
4. Oligonucleotide Pharmacology: Time for a Reboot? 
 
4.1 Identifying off-target actions  
 
The plurality of biological actions mediated via RISC (Fig. 2 and Table 1), and the current 
observations from clinical development of siRNA and ASO therapeutics have questioned the 
generic use of this drug class. It is the view of the authors that these issues are also relevant 
to the laboratory based research using siRNAs, miRNA mimics and, perhaps less so, 
antisense drugs. Crucially, the vast majority of studies fail to demonstrate on-target MOA 
and supporting evidence is provided almost universally in an indirect fashion. From a 
systems pharmacology and toxicology perspective (Cook et al., 2014), confidence in safety 
requires elimination of unintended, off-target mechanisms throughout the drug 
development program, using robust and reproducible methods.  
 
Essential in the process is the use of multiple positive and negative controls. Thus, 
independent verification through alternative tool compounds acting on the same molecular 
target or pools such as multiple siRNA targeting the same gene (Hannus et al., 2014) can be 
employed. Equally, multiple negative controls are also valuable to deconvolute off-target 
phenomena. Unfortunately, common practice appears to be restricted to one or two 
(random or habitual) selections (Table 2).  
 
Crucially, it is also important to continuous assess the potential immunomodulatory actions 
of oligonucleotides and not to restrict these investigations to specific time-points or 
inflammatory markers. One approach proposes the use of alternating modifications of the 
passenger strand as a universal tool for ablating TLR7/8 stimulation by siRNA (Hamm et al., 
2010). This harkens to the immunostimulatory RNA strand logic of isolating TLR7/8 
activation to the passenger strand where this might be mechanistically convenient (Hornung 
et al., 2005), e.g. in anti-viral therapeutics. It is unclear to what extent this is adequate 
beyond TLR7/8 activation and within which cell type/tissue context. It is thus not surprising 
that only two tumor suppressive miRNA analogues, miRNA-16 (TargomiRs; EnGeneIC Ltd.) 
and miRNA-34 (MRX34; Mirna Therapeutics Inc.), have entered clinical trials to date (Lam, 
Chow, Zhang, & Leung, 2015). A modified passenger strand drives careful RISC loading of the 
canonical miRNA-34 guide strand by MRX34 (Daige et al., 2014). Presumably, this also 
enables evasion of TLR7/8 activation. Conversely, modified nucleotides are used in the 5’ 
ends of both strands of the miRNA-16 mimic TargomiRs (Reid et al., 2013), i.e. within the 
seed sequence (Fedorov et al., 2006; Jackson et al., 2006). It is unclear at present to what 
extent the modification strategies adopted with these clinical candidates affect slicer-
independent RNAi pathways, successfully evade TLR recognition or impact on guide strand 
3’ RNA editing common to many miRNAs.  
 
Commented [ML2]: Don’t understand this? 
Are TLR’s 3, 7 and 8 the only concerns of the community? Natural killer cell activation has 
also been reported with synthetic miRNA analogues both in vitro and in vivo (S. He et al., 
2013). Importantly, this report is unusual as the toll-like receptor implicated, TLR1, is not 
understood to be a (oligo)nucleotide pattern recognition receptor. Further studies are 
urgently needed.  
 
One solution proposed to circumvent immune receptor activation has involved the use of 
corticosteroid inhibitors of TLR signaling (Zamora et al., 2011b). This might be questionable 
for some indications but can be advantageous in asthma, chronic obstructive pulmonary 
disease, sarcoidosis and acute lung injury where corticosteroid treatment is recommended, 
or even pulmonary fibrosis due to habitual use (Xaubet et al., 2013). Corticosteroids and 
kinase inhibitors may also be of use in deconvoluting off-target pro-inflammatory response 
induction in drug discovery efforts. 
 
4.2 siRNA therapeutics: The case for next generation in vivo pharmacology. 
The preclinical and clinical studies on pulmonary dosing of siRNA showed that topical 
administration of unmodified compounds could rapidly (<10 min) access circulation and be 
mildly immunogenic. Success was assessed using clinical outcome metrics and not molecular 
pharmacology: no 5’-RACE data in man were disclosed. Thus, it remains unknown if topical 
siRNA administration to the lung in simple formulations such as physiological saline 
(referred to as ‘naked’ siRNA) can drive on-target RNAi in man. Notwithstanding the 
contribution of the immune response by ALN-RSV01 activity, the correct target tissue (nasal 
and lower airways epithelia) was not fully defined, administration methodology was not 
consistent and drug loading was not evidenced directly or followed up adequately given the 
systemic access outcomes.  
 
Separate preclinical studies sought to determine which cell types within the lung were 
differentially loaded with oligonucleotide drugs (Moschos et al., 2011), by using cell sorting 
and confocal microscopy after in vivo dosing. Unlike previous efforts (Lomas-Neira, Chung, 
Wesche, Perl, & Ayala, 2005; Moschos et al., 2007; Perl et al., 2005; Xuchen Zhang et al., 
2004) this group sought to quantify drug uptake and activity in specific cell types relevant to 
lung disease rather than reporting qualitative, low resolution (microscopy), or tissue-level 
data. In addition, the far-red fluorophore used in these studies, sulphonated Cy5, had an 
emission wavelength with very limited tissue fluorescence background, and lower 
lipophilicity (clogD) to plain Cy5. Indeed, lipophilicity is a feature of many siRNA 
modifications like cholesterol (similar molecular weight and clogD to Cy5), which induce 
better cellular uptake of oligonucleotides in vivo (Bijsterbosch et al., 2000; C. Lorenz, 
Hadwiger, John, Vornlocher, & Unverzagt, 2004; Soutschek et al., 2004; Wolfrum et al., 
2007). It was thus shown that although 2’-O-methylated siRNA does indeed interact with 
the lung tissue, it was not subsequently adsorbed, endocytosed or delivered into the cytosol 
of epithelia, alveolar macrophages or endothelia. No biological activity was observed in any 
of the examined cell types, even though the study was powered at >94% (n=5) to measure 
50% reduction in target levels. Instead, mass spectrometry showed that fully intact, 
sulphonated Cy5-labelled siRNA was recovered at substantial quantities within the urine of 
mice within 15 min of intratracheal administration (Moschos et al., 2011). Most 
convincingly, the colour of the urine was deep blue, i.e. the same naked eye colour of the 
sulphonated Cy5 dye. Indeed, a similar, unreported observation in the red (Cy3) spectrum 
(Moschos et al., 2007) had been previously dismissed as incidental hematuria and remained 
uninvestigated. Simple allometric scaling on heart rates between species, would translate 
these findings to siRNA detection in urine ~140 min after administration in man. Although 
direct comparisons of the compounds tested in mice (Moschos et al., 2007, 2011) to ALN-
RSV01 (DeVincenzo et al., 2008; Zamora et al., 2011a) is difficult, rapid (<10 min) circulation 
access in clinical subjects supports a common absorption and elimination mechanism in 
both species. As 5’-RACE was not attempted in these studies, it remains unclear if non-
quantitative 5’-RACE can report residual RNAi and contribute towards misinterpretation of 
off-target phenomena as on-target ‘slicer’ RNAi.  
 
 
5. Concluding remarks and future challenges 
 
At the time of writing, Alnylam programs involving siRNAs-based approaches to the 
treatment of genetic and cardiometabolic disease have eclipsed ALN-RSV01 and associated 
projects, with RSV product development apparently focused in Japan. Elsewhere, attention 
on RNAi mediator therapeutics for the lung has shifted onto solving the problem of cytosolic 
delivery (Clark et al., 2013), whereas ongoing clinical trials in the USA are concerned with 
systemic, non-lung cancer, skin and ocular disorders, almost invariably involving advanced 
drug delivery systems (Lam et al., 2015). Nevertheless, respiratory medicine is rich in 
marketed and clinically advanced candidates, some of which are small molecules cleverly 
designed for topical administration (Jones et al., 2011) and thus are exceptionally 
competitive commercial propositions against modalities with more complex chemistry, 
manufacturing and controls requirements. 
 
The studies on the antisense based AIR645, ASM8 and associated compounds indicated 
effective tissue/cell loading, potentially on-target (mRNA) molecular activity for ASM8 (but 
not necessarily for AIR645) and effective ablation of asthmatic phenotypes. However, no 
explicit 5’-RACE MOA data, evidence of sub-cellular localization was evidenced or ASO 
association with RNase H/intended molecular targets was reported, in line with the so-
called three pillars of drug survival (Morgan et al., 2012) and subsequent emerging 
principles in drug development (Cook et al., 2014). The primary outcome of a phase IIa 
study for AIR645 (NCT00941577) was not met, and Altair Therapeutics was eventually shut 
down. In contrast, the efficacy of ASM8 at phase II has not lead to the termination of the 
programme. A follow up phase II study was withdrawn before enrolment in 2012 
(NCT01380236), however ASM8 is listed as an active programme by Pharmaxis. Importantly, 
none of the adverse events observed with ASM8 were definitively drug-related despite the 
dose-dependent effect on alveolar macrophages, and no complement activation was 
observed (G M Gauvreau et al., 2011). Thus, without recourse to drug delivery systems, the 
FANA antisense chemistry remains presently the most promising candidate in realising the 
clinical potential of oligonucleotide therapeutics for the lung. However, in the absence of 
explicit 5’-RACE data it is presently uncertain that the action of ASM8 can be ascribed, fully 
or in part, on an on-target MOA.  
 
In moving forward, it will also be important to take into consideration that both 2nd and 3rd 
generation ASO are principally loaded in alveolar macrophages, and administration of 2nd 
generation ASO (at least) promotes macrophage accumulation in the airways. Indeed, 
concerns around lung macrophage effects have been upgraded to promote use of 
exploratory inflammatory / toxicology biomarkers (Alton et al., 2012) as encouraged by 
Cook et al. To date, the activation status of resident and recruited macrophages in the lung 
and any chronic tissue effects remain unclear (Forbes et al., 2014). Crucially, macrophage 
recruitment may result in respiratory disease exacerbation (Zasłona et al., 2014), an 
observation of particular relevance to proposed anti-inflammatory antisense therapeutics 
with documented macrophage recruitment propensity such as both the Ionis and Pharmaxis 
chemistries. Moreover, 3rd generation ASO have been very recently shown to harbour an 
off-target class effect that mediates long (>125kb) transcript degradation in an RNase H-
dependent manner (Burel et al., 2015) con-currently to on-target MOA. Thus, clinical 
success for the oligonucleotide therapeutics class in lung disease will pivot on thorough 
exploratory toxicology studies (Cook et al., 2014; Forbes et al., 2014) in vitro, in vivo and 
following chronic exposure trials that effectively compartmentalise on-target value 
proposition against off-target effect tolerability. 
 
Thus far, the history of oligonucleotide therapeutics shows that success hinges on proactive 
pursuit of evidence closely aligned with the so-called 5 pillars of drug discovery (Cook et al., 
2014). The shortest route to the clinic more often than not hides pharmacological 
challenges that can lead to costly, late stage failure. This risk can be managed either through 
documented design approaches (e.g. TLR7/8 avoidance) or systematic screening towards 
clear, hypothesis-driven and exploratory elimination of toxicological and off-target risks. Key 
barriers to success have been perpetuated assumptions around adequate drug exposure 
(pillar 1) and molecular target engagement (pillar 2) extrapolated from tissue loading data, 
as well as neglect over MOA and off-target effect quantification (pillar 3). This is aligned to 
the unfortunate continuation of ‘dogma’ adoption, such as the artificial segregation of the 
molecular functions of slicer-mediated RNAi and miRNA-mediated RNAi (e.g. (Lorenzer, 
Dirin, Winkler, Baumann, & Winkler, 2015), despite calls against this (Moschos, 2013; Sabin 
et al., 2013). Fortunately, companies focusing on oligonucleotide therapeutics are almost 
invariably accurate in selecting the appropriate patient population (pillar 4). However, in the 
absence of orphan indications, as is the case in many lung diseases, the apparent need for 
delivery solutions makes the commercial potential (pillar 5) of this drug class an 
exceptionally challenging proposition. The true impact of the foamy alveolar macrophage, 
and the true need for solutions circumventing its’ elicitation is likely to catalyse ultimate 
success. 
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 Figures 
 
Figure 1: Anatomy of the lung, airway dynamics and drug delivery. A) The nasopharynx, 
trachea and first bronchial bifurcation (upper lung / large airways (>2 mm diameter)) lead to 
conducting airways (< 2 mm diameter: bronchi and bronchioles) that split into alveolar ducts 
(lower / deep lung or small / peripheral airways) (Labiris & Dolovich, 2003). Alveolar ducts 
conclude into alveolar sacs wherein gaseous exchange takes place.  Bronchi and bronchioles 
are ringed tangentially by smooth muscle (R. J. Lorenz, 1966), which controls airflow 
through constriction and relaxation (Gosens & Grainge, 2015), whereas alveolar sacs are 
surrounded by capillaries, forming a short diffusion gradient for gas exchange.  B) Particle 
dimensions and deposition mechanics by airway compartment (Heyder, 2012; Labiris & 
Dolovich, 2003); maximal efficiency is achieved with 1-3 m particles, whereas <500 nm 
particles may diffuse into the alveolar tissue where airflow is low, but are generally exhaled.  
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 Figure 2: Classes of oligonucleotide drugs used in the lung and their mode of action. 
Oligonucleotide therapeutics (bold black lines) recognize molecular targets (red lines) 
through Watson-Crick base pairing. (A) ASO form DNA::RNA heteroduplexes in a sense 
(target) – antisense (drug) manner, recruit RNase H and endonucleotically cleave target RNA 
to create a novel 5’ end (bold), resulting to target degradation and translation inhibition. (B) 
Alternatively, translation inhibition can be directed by targeting ASOs to translation start 
sites in transcripts (AUG box), preventing access to eukaryotic translation initiation factors 
(eIF). Both of these MOAs are active on coding and ncRNA, with stoichiometric inhibition in 
the latter involving steric hindrances to nucleic acid or ribonucleoprotein complex formation 
(C) Premature stop codons, cryptic exons and nonsense mutations (etc.) can be ‘skipped’ by 
directing spliceosome activity. The clinical implementation in Duchenne’s Muscular 
Dystrophy uses ASOs to stop the spliceosome from including an exon (red boxes) containing 
a premature stop mutation (vertical grey line), so that the translated protein may retain 
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some function (Becker phenotype) (Disterer et al., 2014; Q.-L. Lu et al., 2014; van Deutekom 
et al., 2007). (D) The minimal bioactive complex of human RNAi, the RNA-induced silencing 
complex (RISC), consists of a ~21 nt strand of RNA in length (black; ‘active’ or ‘guide’ strand 
(Gu et al., 2011; Khvorova, Reynolds, & Jayasena, 2003; Krol et al., 2004)) loaded into one of 
the four Argonaute (AGO) proteins (Kawamata & Tomari, 2010) from an endogenous 
(miRNA) or exogenous (siRNA) dsRNA precursor. The reverse complement ‘passenger’ 
strand (blue) is discarded. The outcome of target interaction with RISC depends on the AGO 
component, site of RISC interaction within the target (e.g. coding or untranslated regions 
(UTR)), degree of complementarity and subcellular complex localization, i.e the cytosol (blue 
functions) or the nucleus (RED functions). 
 
 
 
 Figure 3: Key backbone and nucleoside modifications used in oligonucleotide 
therapeutics. (A) The most popular oligonucleotide modification (orange) of oligonucleotide 
backbones replaces one oxygen with a sulfur group. Morpholinos (PMO) have an uncharged 
backbone and six-membered rings replacing riboses that do not impact on solubility, appear 
to increase affinity (melting temperatures with RNA targets, ~20oC increase per ASO 
(Summerton & Weller, 1997)). The MOA of PMO is restricted to RNase H-free mechanisms 
(J. Summerton, 1999) and involves translation inhibition, splice switching and miRNA 
blockade  (Eisen & Smith, 2008). Peptide nucleic acids (PNA) use entirely acyclic backbones 
conveying generally neutral charge and robust nuclease resistance and improve target 
affinity (Nielsen, Egholm, Berg, & Buchardt, 1991), evidenced even in siRNA modification 
(Gong & Desaulniers, 2012). They direct non-RNase H MOA (Uhlmann, 1998)  in eukaryotes 
and prokaryotes (Pooga, Land, Bartfai, & Langel, 2001). (B) Nucleoside modifications have 
principally involved substitution of the 2’ H (DNA) or OH (RNA) group with more 
complicated alkyl groups, but also 2’-5’ linking groups and 2’ arabinose stereoisomers such 
as the 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2’-fluoroarabino, or FANA) chemistry.   
 
 
Figure 4: The three generations of antisense oligonucleotides. (A) Uniform modification of 
the ASO backbone from phosphorothioate (black line) to phosphodiester (green line; first 
generation) enabled better retention in circulation, significant loading in the liver and 
kidney and in vivo activity without delivery systems (Beltinger et al., 1995; Cossum et al., 
1993; Crooke et al., 1996; Nolting et al., 1997) at a small cost of affinity for targets 
(Summerton & Weller, 1997). (B) Second generation, 2’-modified ASOs retain backbone 
modifications, are typically 20-30 nt long and are structured either with modifications 
(orange nucleosides) interspersed in the ASO (mixomers) or as a central 6-8 nucleoside 
stretch with no ribose modifications and flanked at the 5’ and 3’ ends with 2’- modified 
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nucleosides (gapmers). (C) Third generation 2’-5’ chemistries (blue nucleosides) impart 
conformational rigidity that greatly enhances ASO affinity to their targets, increasing 
melting temperatures by as much as 4-8 oC per modified nucleoside (Kumar et al., 1998). 
Consequently, shorter ASO (e.g. 16-20 nt) can match or even outperform longer (20-30 nt) 
2nd generation equivalents: bridged nucleosides force ASO not to tolerate base mismatches 
with their targets, thereby improving specificity (Valoczi et al., 2004). Short 100% modified 
octamers (tiny) may block entire miRNA classes with common seed sequences en masse 
(Obad et al., 2011).  
 
 
 
Figure 5: microRNA organization and maturation into bioactive RISC. (A) miRNA arise from 
exons (blue boxes) or introns (light blue angled lines). Some short introns can encode 
miRNA (mirtrons), whereas other miRNA precursors arise from exon-intron junctions, or 
A)	
Exonic:	 7mG-	 -A(n)	
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span entire short exons (exon-overlap). Yet others are processed out of 5’ and 3’ UTRs. (B) 
Endogenous RNAi mediator transcripts typically form stem-loop hairpin structures (primary 
miRNA) excised by the microprocessor complex in the nucleus into pre-miRNA and actively 
transported to the cytosol by Exportin 5. Here, the loop is endonucleotically removed by 
Dicer to form miRNA and then loaded onto AGO to form RISC; guide strand selection is 
driven by the orientation of the duplex loading onto AGO. Notable updates involve 
mitochondrial ncRNA-derived miRNA (mito-miRs) (Jagannathan et al., 2015; Ro et al., 2013), 
as well as AGO-directed small ncRNA (AGO-taxic ncRNA) of distinct genomic origin, but 
uniquely equipped to select AGO partners in RISC formation (Yamakawa et al., 2014). Small 
interfering RNA and miRNA replacement therapy can be achieved by gene therapy 
approaches exploiting any of these genomic organization structures or by providing 
exogenous, synthetic RNA (e.g. hairpins, duplexes) that engage with the latter processing 
steps of miRNA biogenesis. Adapted from (Moschos, 2013). 
 
 
 
 
 
 
 
 
 
 
  
Table 1: Innate immune receptors for RNA and DNA oligonucleotide therapeutics. 
Receptor Location Minimal motif 
Oligonucleotide class 
affected Evasion solution Reference(s) 
TLR1 Cell surface Unknown miRNA analogues Unknown He et al. 2013 
 
TLR3 Cell surface > 19 nt siRNA, dsRNA N6-methyladenosine, 
2-thiouridine 
Cho et al., 2009; Kleinman et al., 2008; 
Karikó et al., 2005 
 
TLR7/8 Cell surface UG siRNA, miRNA, ASO 2' ribose modification, 
N6-methyladenosine, 
2-thiouridine 
Hornung et al., 2005; Judge et al., 2005; 
Fedorov et al. 2006; Jackson et al. 2006 
 
 
TLR9 Cell surface unmethylated 
CpG motifs 
DNA ASO CpG methylation Krieg et al. 1995; Rutz et al 2004 
 
 
RIG-I Cytosolic blunt duplex 
ends; 5' 
triphosphate 
siRNA, dsRNA 3' dinucleotide 
overhangs, no 5' 
triphosphates 
Marques et al., 2006; Kato et al., 2008 
 
 
 
MDA5 Cytosolic > 30 nt dsRNA short sequences Kato et al., 2008 
 
PKR Cytosolic > 30 nt dsRNA short sequences Sledz et al., 2003 
 
OAS1 Cytosolic NNWW(N9)WGN  siRNA, miRNA, RNA ASO Design Kodym et al., 2009 
 
DAI Cytosolic > 30 nt dsRNA short sequences Manche et al., 1992 
 
 
Table 2: Types of negative controls for oligonucleotide therapeutics. 
 
Control type* Examples Key features 
Scrambled 5’-CUGGUUAGUGGCACUUCGAUU-3’ to   impact increases with scrambling amount 
 5’-CGUGUUAGUGGCACUUCGAUU-3’  may require >1 controls 
   avoid accidental host gene targeting 
   scramble 10-11 / central octamer to create slicer 
/ RNase H control 
 
Mismatch 5’-AUGGUUAGUGGCACUUCGAUU-3’ to   seed region placement alters off targets** 
 
5’-ACUGUUAGUGGCACUUCGAUU-3’  slicer / RNase H active site inhibition 
  
 >1 controls also recommended 
 
Reverse 5’-CUGGUUAGUGGCACUUCGAUU-3' to   check for unintended host hits 
 5'-UUAGCUUCACGGUGAUUGGUC-3'  no complementarity to intended target 
 
Validated  Green fluorescent protein, luciferase,   target not normally found in host transcriptome 
bioactive oligo Arabidopsis thaliana, C. elegans  confirm lack of complementarity 
   confirm no seed sequence in pathway of interest 
 
Commercial negative  Research supplier 'universal' negative   limited 'negative' validation 
control controls  unknown modifications 
     unknown sequence 
*: Must match design and modification criteria of active oligonucleotide. 
**: Relevant to RNAi mediators only. 
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